There are currently 2877 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
NCT06083883
Recruiting
The goal of this clinical research study is to find a recommended dose of donated NK cells that can be given along with chemotherapy to patients with advanced cancers. The safety and effects of this therapy will also be studied.
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
04/09/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Synovial Sarcoma, Myxoid/Round Cell Liposarcoma
Register for Updates
Use Electroencephalogram to Study Neural Dynamics of Fear Conditioning and Avoidance Learning Circuit in Humans
NCT06240052
Recruiting
The purpose of this study is to examine which event-related potentials (ERPs) and event-related oscillations (EROs) are associated with fear conditioning, avoidance learning, and memory recall for fear and avoidance, where are the source generators of the observed scalp EEG activity, the impact of fear and avoidance learning on the decision to avoid or not to avoid conditioned stimuli , to examine the large-scale functional connectivity across distributed brain regions across experimental phases... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/09/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Neural Dynamics of the Acquisition and Retention of Fear Learning and Active Avoidance Learning
Register for Updates
A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
NCT06308419
Recruiting
To find a recommended dose of gemcitabine and nab-sirolimus that can be given in combination to participants with advanced leiomyosarcomas or soft-tissue sarcomas.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Leiomyosarcoma, Soft-tissue Sarcomas
Register for Updates
A Study of VET3-TGI in Patients With Solid Tumors
NCT06444815
Recruiting
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with pembrolizumab in patients with solid tumors (STEALTH-001).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Kidney Cancer, Renal Cell Carcinoma, Melanoma Stage IV, Merkel Cell Carcinoma of Skin, Mesothelioma, Non-small Cell Lung Cancer
Register for Updates
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
NCT06795022
Recruiting
This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GPC3+.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Research Site, Houston, Texas
Conditions: Hepatocellular Carcinoma
Register for Updates
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
NCT05125016
Recruiting
This study is researching an investigational drug called REGN4336. Some participants may receive additional investigational drugs in combination with REGN4336. These additional drugs include REGN5678, cemiplimab and sarilumab. The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug) and effectiveness of REGN4336 alone, in combination with cemiplimab, or in combination with REGN5678. REGN4336, cemiplimab and REGN5678 are a type of treatment for ca... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/08/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
ETHAN - ET for Male BC
NCT05501704
Recruiting
This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer. The drugs used in this study are: * Tamoxifen * Anastrozole * Degarelix * Abemaciclib
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/08/2025
Locations: M. D. Anderson Cancer Center at University of Texas, Houston, Texas
Conditions: Male Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
Register for Updates
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
NCT05568680
Recruiting
This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/08/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Ovarian Cancer, Cholangiocarcinoma Recurrent, Mesothelioma, Malignant
Register for Updates
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
NCT06364410
Recruiting
This phase I trial tests the safety, side effects, and best dose of azenosertib in combination with trastuzumab deruxtecan in treating patients with HER2-positive and cyclin E amplified gastric or gastroesophageal junction cancer and other HER2-positive solid tumors that have spread to nearby tissue or lymph nodes (locally advanced), that have spread from where it first started (primary site) to other places in the body (metastatic), or that cannot be removed by surgery (unresectable). Azenosert... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/08/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Gastric Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm
Register for Updates
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
NCT06507306
Recruiting
The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * What happens to KQB198 in the body? Participants will: * Take KQB198 daily, alone or in combination with an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/08/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumor, Adult
Register for Updates
Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve Provider Recommendation and HPV Vaccination Rates Among Latino/a Adolescents
NCT06598475
Recruiting
The purpose of this study is to determine the provider- and practice-level characteristics that influence the impact of implementation strategies guided by practice facilitation in each clinical practice, to test whether the facilitator-driven provider- and practice-level implementation strategies increase provider recommendations and Human Papilloma Virus (HPV) vaccination rates and to evaluate implementation and future sustainability of the facilitator-driven implementation strategies across n... Read More
Gender:
ALL
Ages:
Between 11 years and 17 years
Trial Updated:
04/08/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Human Papillomavirus Infection
Register for Updates
Rethinking Rigidity: Development of a 3D-Printed Scoliosis Brace With Varying Flexibility
NCT06785207
Recruiting
Scoliosis bracing is an effective treatment method for idiopathic scoliosis, but only if worn consistently for many hours a day. Unsurprisingly, brace discomfort is a significant deterrent against treatment adherence. For decades, custom braces for idiopathic scoliosis have been fabricated using one of three materials - copolymer, polypropylene, or polyethylene. The application of the biomechanical principles behind bracing have improved over the years, but the materials have not. The investigat... Read More
Gender:
ALL
Ages:
Between 8 years and 18 years
Trial Updated:
04/08/2025
Locations: University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Scoliosis Idiopathic Adolescent Treatment
Register for Updates